Abstract
Decades of research have established only a few etiological factors for glioma, which is a rare and highly fatal brain cancer. Common methodological challenges among glioma studies include small sample sizes, heterogeneity of tumor subtypes, and retrospective exposure assessment. Here, we briefly describe the Glioma International Case-Control (GICC) Study (recruitment, 2010-2013), a study being conducted by the Genetic Epidemiology of Glioma International Consortium that integrates data from multiple data collection sites, uses a common protocol and questionnaire, and includes biospecimen collection. To our knowledge, the GICC Study is the largest glioma study to date that includes collection of blood samples, which will allow for genetic analysis and interrogation of gene-environment interactions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-91 |
| Number of pages | 7 |
| Journal | American journal of epidemiology |
| Volume | 183 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 15 2016 |
Keywords
- cancer
- case-control studies
- glioblastoma
- glioma
- methodology
- study profile
ASJC Scopus subject areas
- Epidemiology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'The Glioma International Case-Control Study: A Report from the Genetic Epidemiology of Glioma International Consortium'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of epidemiology, Vol. 183, No. 2, 15.01.2016, p. 85-91.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The Glioma International Case-Control Study
T2 - A Report from the Genetic Epidemiology of Glioma International Consortium
AU - Amirian, E. Susan
AU - Armstrong, Georgina N.
AU - Zhou, Renke
AU - Lau, Ching C.
AU - Claus, Elizabeth B.
AU - Barnholtz-Sloan, Jill S.
AU - Il'Yasova, Dora
AU - Schildkraut, Joellen
AU - Ali-Osman, Francis
AU - Sadetzki, Siegal
AU - Johansen, Christoffer
AU - Houlston, Richard S.
AU - Jenkins, Robert B.
AU - Lachance, Daniel
AU - Olson, Sara H.
AU - Bernstein, Jonine L.
AU - Merrell, Ryan T.
AU - Wrensch, Margaret R.
AU - Davis, Faith G.
AU - Lai, Rose
AU - Shete, Sanjay
AU - Amos, Christopher I.
AU - Scheurer, Michael E.
AU - Aldape, Kenneth
AU - Alafuzoff, Irina
AU - Brännström, Thomas
AU - Broholm, Helle
AU - Collins, Peter
AU - Giannini, Caterina
AU - Rosenblum, Marc
AU - Tihan, Tarik
AU - Melin, Beatrice S.
AU - Bondy, Melissa L.
N1 - Funding Information: Author affiliations: Department of Pediatrics, Division of Hematology-Oncology, Dan L. Duncan Cancer Center, Baylor College ofMedicine,Houston, Texas (E. SusanAmirian, Georgina N. Armstrong, Renke Zhou, Ching C. Lau, Michael E. Scheurer, Melissa L. Bondy); Department of Epidemiology and Public Health, School of Medicine, Yale University, New Haven, Connecticut (Elizabeth B. Claus); Department of Neurosurgery, Brigham and Women’s Hospital, Boston, Massachusetts (Elizabeth B. Claus); Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio (Jill S. Barnholtz-Sloan); Department of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia (Dora Il’yasova); Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina (Dora Il’yasova, Joellen Schildkraut); Department of Surgery, Duke University Medical Center, Durham, North Carolina (Francis Ali- Osman); Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel (Siegal Sadetzki); Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel (Siegal Sadetzki); Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark (Christoffer Johansen); Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Christoffer Johansen, Helle Broholm); Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom (Richard S. Houlston, Caterina Giannini); Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic,Rochester, Minnesota (Robert B. Jenkins); Department of Neurology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota (Daniel Lachance); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (Sara H. Olson, Jonine L. Bernstein); Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois (Ryan T. Merrell); Department of Neurological Surgery, School of Medicine, University of California, San Francisco, San Francisco, California (Margaret R.Wrensch); Department of Public Health Services, School of Public Health, University of Alberta, Edmonton, Alberta, Canada (Faith G. Davis); Departments of Neurology, Neurosurgery, and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California (Rose Lai); Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (Sanjay Shete); Department of Community and Family Medicine, Department of Genetics, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire (Christopher I. Amos); Department of LaboratoryMedicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (Kenneth Aldape); Department of Immunology, Genetics, and Pathology, Faculty of Medicine, Uppsala University, Uppsala, Sweden (Irina Alafuzoff ); Department of Medical Biosciences, Faculty of Medicine, Umeå University, Umeå, Sweden (Thomas Brännström); Department of Pathology, Cambridge Cancer Centre, University of Cambridge, Cambridge, United Kingdom (Peter Collins); Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Marc Rosenblum); Department of Pathology, School of Medicine, University of California, San Francisco, San Francisco, California (Tarik Tihan); and Department of Radiation Sciences, Faculty of Medicine, Umeå University, Umeå, Sweden (Beatrice S. Melin). This work was supported by grants from the National Institutes of Health (grants R01CA139020, R01CA52689, P50097257, and P30CA125123). Additional support was provided by the McNair Medical Institute at Baylor College of Medicine (Houston, Texas) and the Population Sciences Biorepository at Baylor College of Medicine. The Glioma International Case-Control Study is being conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each study subject or from his/her guardian. Approval from local institutional review boards was received at each institution participating in the Genetic Epidemiology of Glioma International Consortium. Publisher Copyright: © 2015 The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved.
PY - 2016/1/15
Y1 - 2016/1/15
N2 - Decades of research have established only a few etiological factors for glioma, which is a rare and highly fatal brain cancer. Common methodological challenges among glioma studies include small sample sizes, heterogeneity of tumor subtypes, and retrospective exposure assessment. Here, we briefly describe the Glioma International Case-Control (GICC) Study (recruitment, 2010-2013), a study being conducted by the Genetic Epidemiology of Glioma International Consortium that integrates data from multiple data collection sites, uses a common protocol and questionnaire, and includes biospecimen collection. To our knowledge, the GICC Study is the largest glioma study to date that includes collection of blood samples, which will allow for genetic analysis and interrogation of gene-environment interactions.
AB - Decades of research have established only a few etiological factors for glioma, which is a rare and highly fatal brain cancer. Common methodological challenges among glioma studies include small sample sizes, heterogeneity of tumor subtypes, and retrospective exposure assessment. Here, we briefly describe the Glioma International Case-Control (GICC) Study (recruitment, 2010-2013), a study being conducted by the Genetic Epidemiology of Glioma International Consortium that integrates data from multiple data collection sites, uses a common protocol and questionnaire, and includes biospecimen collection. To our knowledge, the GICC Study is the largest glioma study to date that includes collection of blood samples, which will allow for genetic analysis and interrogation of gene-environment interactions.
KW - cancer
KW - case-control studies
KW - glioblastoma
KW - glioma
KW - methodology
KW - study profile
UR - http://www.scopus.com/inward/record.url?scp=84960080630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960080630&partnerID=8YFLogxK
U2 - 10.1093/aje/kwv235
DO - 10.1093/aje/kwv235
M3 - Article
C2 - 26656478
AN - SCOPUS:84960080630
SN - 0002-9262
VL - 183
SP - 85
EP - 91
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 2
ER -